AstraZeneca PLC announced on Tuesday that its revenue in the fourth quarter of fiscal 2025 stood at $15.5 billion, rising by 4% compared to the same quarter in the previous year and slightly exceeding expectations.
The pharmaceutical company's diluted earnings per share (EPS) rose by 55% year-on-year to land at $1.49 in the reported quarter, while its operating profit reached $3 billion, jumping by 46.3% compared to the previos year.
For the full year 2025, AstraZeneca's revenue came in at $58.7 billion, increasing by 9% compared to full year 2024, while the diluted earnings per share soared by 45% to $6.60.
"In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines," CEO Pascal Soriot said.
https://breakingthenews.net/Article/AstraZeneca's-Q4-revenue-up-4-to-dollar15.5B/65636174
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.